<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03195673</url>
  </required_header>
  <id_info>
    <org_study_id>TZ-CAS</org_study_id>
    <nct_id>NCT03195673</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Low Dosage of Terazosin in Subjects Undergoing Carotid Artery Stenting</brief_title>
  <acronym>TZ-CAS</acronym>
  <official_title>A Pilot Study Assessing the Safety and Efficacy of Low Dosage of Terazosin in Subjects Undergoing Carotid Artery Stenting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Luhe Teaching Hospital of the Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Capital Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of low dosage of Terazosin in
      Carotid Artery Stenting
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2018</start_date>
  <completion_date type="Anticipated">December 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants who got New DWI Lesions (MRI)</measure>
    <time_frame>Within 48 hours after carotid artery stenting</time_frame>
    <description>Patients who got new ischemic lesions as defined by DWI MRI within 48 hours after carotid artery stenting</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of New DWI Lesions (MRI)</measure>
    <time_frame>Within 48 hours after carotid artery stenting</time_frame>
    <description>Number of new ischemic lesions as defined by DWI MRI within 48 hours after carotid artery stenting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of New DWI Lesions (MRI)</measure>
    <time_frame>Within 48 hours after carotid artery stenting</time_frame>
    <description>Volume of new ischemic lesions as defined by DWI MRI within 48 hours after carotid artery stenting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with New DWI Lesions (MRI) diameter greater than 5mm</measure>
    <time_frame>Within 48 hours after carotid artery stenting</time_frame>
    <description>Patients who got new ischemic lesions diameter greater than 5mm as defined by DWI MRI within 48 hours carotid artery stenting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with Cerebrovascular Events, Cardiovascular Events or Death.</measure>
    <time_frame>From baseline to 30 days after treatment</time_frame>
    <description>Cerebrovascular events included ischemic stroke, transient ischemic attack (TIA), cerebral hemorrhage and hyperperfusion syndrome. Cardiovascular events included angina and myocardial infarction. Death included any reason caused death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Examination</measure>
    <time_frame>Before and 24 hours after carotid artery stenting</time_frame>
    <description>Laboratory Examination before and post-treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients underwent hypertensive treatment due to post-procedure hypotention</measure>
    <time_frame>0-7 days or discharge which comes early</time_frame>
    <description>Number of Patients underwent hypertensive treatment due to post-procedure hypotention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with Any Side Events</measure>
    <time_frame>From baseline to 30 days after treatment</time_frame>
    <description>Any side events caused by TZ, regular treatment or CAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>From baseline to 30 days after treatment</time_frame>
    <description>Any cause of death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Carotid Artery Stenosis</condition>
  <arm_group>
    <arm_group_label>TZ group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment:Patients in this group received standard medical therapy and Terazosin (TZ) treatment.
Drug: TZ 0.5mg once a day for 3-7 days before carotid artery stenting to 30 days later.
Procedure: Carotid Artery Stenting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment: Patients in this group received standard medical therapy alone. Procedure: Carotid Artery Stenting</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terazosin</intervention_name>
    <description>TZ 0.5mg once a day for 3-7 days before carotid artery stenting to 30 days later.</description>
    <arm_group_label>TZ group</arm_group_label>
    <other_name>TZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Carotid artery stenting</intervention_name>
    <description>Carotid artery stenting is an alternative treatment of carotid artery stenosis, which would be performed by experienced neuroradiologist according to the latest guideline from American Heart Association and American Stroke Association.</description>
    <arm_group_label>TZ group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
    <other_name>CAS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Symptomatic or asymptomatic carotid artery stenosis. In symptomatic patients the
             degree of stenosis should more than 50% (Based on NASCET Criteria), in asymptomatic
             patients the degree of stenosis should more than 70% (Based on NASCET Criteria);

          2. Tolerance to any of the study medications, including TZ, clopidogrel, aspirin and
             statins;

          3. Hypertensive patients with or without oral antihypertensive drugs

          4. Can cooperate with and complete brain MRI examination;

          5. Stable vital signs, cardiopulmonary, liver and kidney function was no obvious
             abnormalities;

          6. Has a negative pregnancy test within 7 days before randomization and no childbearing
             potential;

          7. Stable vital sign, normal renal and hepatic functions;

          8. Informed consent.

        Exclusion Criteria:

          1. Evolving stroke;

          2. Hemorrhagic tendencyï¼›

          3. Severe dementia or Prior major ipsilateral stroke, if likely to confound study
             endpoints;

          4. Chronic atrial fibrillation or any other Cardiogenic emboli source disease;

          5. Myocardial infarction within previous 30 days;

          6. Spontaneous Intracerebral Hemorrhage within the past 180 days, Hemorrhagic conversion
             of an ischemic stroke within the past 60 days or recent (&lt;7 days) large area cerebral
             infarction has a hemorrhagic conversion tendence;

          7. Any conditions that hampers proper angiographic assessment or makes percutaneous
             arterial access unsafe;

          8. High risk candidates of CAS defined as the Carotid Revascularization Endarterectomy
             vs. Stenting Trial (CREST);

          9. Thiazides taken within 14 days before randomization;

         10. Participating in any other clinical trial that has not completed the required protocol
             follow-up period;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xunming Ji, MD PhD</last_name>
    <phone>+86-83198952</phone>
    <email>jixunming@vip.163.com; jiangfanghappy@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fang Jiang, MD</last_name>
    <email>jiangfanghappy@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>He Yin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Luhe Teaching Hospital of the Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>101100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaokun Geng, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>June 20, 2017</study_first_submitted>
  <study_first_submitted_qc>June 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2017</study_first_posted>
  <last_update_submitted>December 9, 2018</last_update_submitted>
  <last_update_submitted_qc>December 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xuanwu Hospital, Beijing</investigator_affiliation>
    <investigator_full_name>Ji Xunming,MD,PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Carotid artery stenting</keyword>
  <keyword>Silent embolism</keyword>
  <keyword>Terazosin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carotid Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terazosin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

